Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Strengthening focus in Alzheimer's disease and neuroscience pipeline
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Subscribe To Our Newsletter & Stay Updated